• Asian Pacific Journal of Cancer Prevention
• /
• 제15권24호
• /
• pp.10831-10836
• /
• 2015

This study was conducted to establish whether the preoperative platelet to lymphocyte ratio (PLR) is predictive of survival of women with ovarian clear cell carcinoma (OCCC). A PLR > 300 was deemed elevated. Progression-free survival (PFS) was estimated using the Kaplan-Meier method. Cox proportional hazard analysis was used to determine the independent effect of PLR. Thirty-six patients were reviewed. Elevated PLRs were more commonly noted in patients with an advanced vs an early stage of disease (88.9% vs 11.1%). Women with elevated PLR carried a higher rate of disease progression during primary therapy than that those in the normal PLR group (44.4 vs 22.2%). The median PFS for patients with elevated PLR was notably worse than that for patients with normal PLR (10 vs 34 months). Despite the impact of elevated PLR on PFS, it was found to be marginally significant when controlling for commonly applied prognostic markers. It, however, trended toward significance (HR=4.76; 95%CI, 0.95-23.8). In conclusion, an elevated PLR appears to be directly associated with adverse survival rather than being a surrogate for other indicators of a poor prognosis. PLR may be a useful biomarker for predicting survival of women with OCCC and merits further large-scale studies.

• Clinical and Experimental Reproductive Medicine
• /
• 제41권2호
• /
• pp.92-95
• /
• 2014

Objective: This study sought to evaluate platelet volume indices (mean platelet volume [MPV], platelet distribution width [PDW], and platelet large cell ratio [P-LCR]) in varicocele patients, and compare it with platelet volume parameters in healthy controls. Methods: This cross-sectional study involved 2 groups: group 1 included 51 varicocele subjects and group 2 consisted of 50 healthy control subjects of similar ages. Peripheral venous blood samples were collected with ethylenediaminetetraacetic acid-K2 anticoagulant between 8:30 AM and 10 AM following an overnight fast. Platelet volume parameters (MPV, PDW, and P-LCR) were measured in both groups within 2 hours of sampling. Results: The mean PDW, MPV, and P-LCR were $13.9{\pm}2.5%$, $10.1{\pm}1.3fL$, and $27.3{\pm}7.8%$ in varicocele patients, respectively, and were $12.6{\pm}2.4%$, $9.3{\pm}1.1fL$, and $21.9{\pm}6.4%$ in the control group, respectively. The mean PDW, MPV, and P-LCR were significantly higher in the varicocele group than the control group. Conclusion: The results of the present study suggest that vascular components may play an important role in the pathophysiology of varicocele; therefore, there is a great need for prospective studies to confirm this relationship.

• 대한임상검사과학회지
• /
• 제50권4호
• /
• pp.399-405
• /
• 2018

임상검사실에서의 혈소판 수 계산은 지혈이상의 진단과 치료에 필수적이며, 혈소판 수가 적은 경우 혈소판 수혈이 필요하고 항암치료 후 혈소판 수 경과를 모니터링하는데 매우 중요하다. 정도관리는 환자결과를 내보내기 전에 검사실에서 오류를 줄이고 교정하는 과정이며 분절된 적혈구는 혈소판과 크기가 비슷하여 혈소판 수 계산에 영향을 미친다. 검사실에서 내부정도관리low QC물질이 2SD를 벗어난 것을 경험하였고, 지금까지 용혈과 혈소판 지표들과의 관계에 대해 밝혀진 것이 충분하지 않아 연구를 시작하였다. 이에 본 연구에서는 XN CHECK low level QC물질을 이용해 PLT-I, PLT-O, PLT-F 방법간의 혈소판 수치를 비교하였으며, 용혈검체를 만들어 5가지 혈소판지표들에 대해 비교분석 하였다. 그 결과PLT-F방법에서 CV값이 가장 적게 나타났으며, 용혈검체에서 P-LCR 수치가 18.4%에서 31.9%로 증가함을 보였다. 이 연구를 통해 혈소판 수치가 낮은 경우는 PLT-F방법으로 하는 것이 더 정확하며, 검체가 용혈이나 변질이 의심되는 경우 이를 평가할 때 P-LCR을 새로운 지표로 제시하고 있으며, 사람 혈액검체를 이용한 추후 연구가 더 필요할 것이라고 사료된다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권14호
• /
• pp.5945-5950
• /
• 2015

A 6-year retrospective cohort study was conducted among Thai hematologic malignancy (HM) patients receiving intensive chemotherapy. Of the 145 eligible patients receiving 893 chemotherapy sessions, 46.9% were female, median age was 52 years, and the most common HM diagnosis was diffuse large B-cell lymphoma (46.2%). Febrile neutropenia (FN) occurred in 14.9% of chemotherapy sessions with an incidence of 24.8 per 1,000 chemotherapy cycles per year. Independent factors associated with FN were receiving the first chemotherapy cycle [adjusted hazard ratio (aHR) 4.1], having hemoglobin ${\leq}100g/L$ (aHR 3.7) and platelet ${\leq}140,000/{\mu}L$ (aHR 2.7) on chemotherapy day and receiving acute myeloid leukemia regimens (aHR 20.8). Granulocyte colony stimulating factor was significantly associated with reduced rate of FN when given in those receiving CHOP regimen. With the median follow-up time of 16 months, the overall survival time was significantly longer in patients without FN than those with FN (61.7 vs. 20.8 months; p<0.001).